Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BCTX
BRIACELL THERAPEUTICS CORP.
NASDAQ
$3.73
▲ UP 0.54% (0.02)

KEY STATISTICS

Market Cap$32.45 M
52w High$14.68
52w Low$2.60
Dividend Yield—
Frequency—
P/E-0.20
Volume234.80K
Shares Out.8.70M

COMPANY

LEADERSHIP

William V. Williams
CHIEF EXECUTIVE
William V. Williams

COMPENSATION 2026

Salary$711,724
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$780,622

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 14, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
16

SPLIT RECORD

DATETYPERATIO
2025-08-25Reverse1:10
2025-01-29Reverse1:15
2020-01-02Reverse1:300
2014-12-03Reverse307:1000

PRICE

$3.73 ▲ UP 0.54% (+$0.02)
OVERLAYS
$3.60$3.65$3.70$3.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.73

About BriaCell Therapeutics Corp.

https://www.briacell.com ↗

BriaCell Therapeutics Corp. is a Canadian immuno-oncology biotech developing cancer immunotherapies, including Bria-IMT for breast cancer, with collaborations on personalized treatments and diagnostics.

INDUSTRY

Biotechnology

A PRODUCT BRIACELL THERAPEUTICS CORP. IS KNOWN FOR

Bria-IMT™
Bria-IMT™

Bria-IMT™ is BriaCell's targeted immunotherapy for metastatic breast cancer, in Phase 3 trials with FDA Fast Track status, aiming to stimulate the immune system to attack cancer cells.

COMPETITORS

COMPETITOR
CADL COMPARE
IBRX COMPARE
IOVA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
FO
FOMO
1.24% · 11.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.00%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Covington Capital Management
1 sh · $0

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

SECTORS PEERS

PEERPRICE
PALI$2.00COMPARE
ALLR$1.41COMPARE
CTXR$0.60COMPARE
PCSA$2.06COMPARE
MBRX$0.65COMPARE
CRIS$1.49COMPARE
ASBP$8.51COMPARE